Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
APVO
Aptevo Therapeutics Inc.
APVO's lead therapies are bispecific antibodies (and trispecifics) designed to engage T cells and tumor targets using its ADAPTIR/ADAPTIR-FLEX platforms.
|
$4.21M |
$1.28
+7.08%
|
|
DFCO
Dalrada Financial Corporation
Infusion pharmacy and compounding facility fall under healthcare services & facilities.
|
$4.21M |
$0.04
|
|
EVTV
Envirotech Vehicles, Inc.
Medical Device Consumables: Medical supplies segment with related-party sales and cost-plus pricing indicating consumable offerings.
|
$4.20M |
$1.24
+8.33%
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$4.20M |
$1.96
+2.08%
|
|
RMSL
REMSleep Holdings, Inc.
RMSL designs and manufactures CPAP-based respiratory medical devices (DeltaWave), directly aligning with 'Medical Devices & Biometrics'.
|
$4.13M |
$0.00
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$4.10M |
$0.04
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$4.09M |
$1.37
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$4.03M |
$0.64
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$3.81M |
$0.86
|
|
NAKA
Kindly MD, Inc.
Provides patient-first healthcare services and operates clinics/delivery of care under KindlyMD.
|
$3.79M |
$0.50
+8.18%
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.76M |
$0.94
-0.04%
|
|
GTCH
GBT Technologies Inc.
GTCH's qTerm device and biometrics relate to medical devices/biometrics category.
|
$3.70M |
$0.00
|
|
VERO
Venus Concept Inc.
Venus Concept produces medical aesthetic devices and robotic systems (Venus platforms, ARTAS iX) and related medical devices.
|
$3.57M |
$1.92
+0.52%
|
|
NAOV
NanoVibronix, Inc.
Core business is medical devices, including legacy wound/pain therapies and new ENvue enteral-feeding technology.
|
$3.35M |
$4.02
-19.28%
|
|
STSS
Sharps Technology, Inc.
Core product category: Safety syringes (SafeGard/Sologard) with passive safety features.
|
$3.35M |
$3.30
+4.43%
|
|
MHUA
Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies' core business is the manufacturing and sale of disposable medical device consumables.
|
$3.04M |
$10.80
-7.41%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.94M |
$0.59
-0.90%
|
|
CRVW
CareView Communications, Inc.
CareView's core offering is patient monitoring via video-based systems, including SitterView and TeleMedView components.
|
$2.93M |
$0.03
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.78M |
$1.29
+4.03%
|
|
VTAK
Catheter Precision, Inc.
VTAK's VIVO System is a cardiology-focused medical device for non-invasive 3D mapping, aligning with Cardiology Devices.
|
$2.52M |
$2.07
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$2.38M |
$0.01
|
|
SOBR
SOBR Safe, Inc.
SOBR directly manufactures biometric-enabled medical devices (SOBRcheck) and wearable monitoring hardware (SOBRsure) paired with a cloud software platform.
|
$2.35M |
$1.59
+11.19%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$2.24M |
$5.16
-1.62%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.18M |
$0.40
|
|
AAGH
America Great Health
Joint venture and activities in cell therapy and regenerative medicine.
|
$2.12M |
$0.00
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$1.98M |
$0.05
|
|
SGBX
Safe & Green Holdings Corp.
Medical segment includes point-of-care solutions and the Sanitec disinfecting system, aligning with Medical Devices & Biometrics.
|
$1.88M |
$3.87
+21.32%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$1.88M |
$0.15
+162.03%
|
|
ZCMD
Zhongchao Inc.
ZCMD provides healthcare information services and patient management systems to healthcare professionals and institutions, fitting Healthcare Services & Facilities.
|
$1.72M |
$0.60
-2.44%
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$1.69M |
$0.35
+3.90%
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.59M |
$0.93
+10.81%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.56M |
$5.95
+0.17%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.45M |
$1.36
+2.26%
|
|
BIAF
bioAffinity Technologies, Inc.
The company operates clinical laboratory testing facilities as part of CyPath Lung, aligning with 'Clinical Lab Chains'.
|
$1.38M |
$1.46
+2.10%
|
Showing page 37 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
